GSK in 50:50 JV with Biological E for developing paediatric vaccine

MUMBAI: World's fourth largest drug maker GlaxoSmithKline has teamed up with Hyderabad-based vaccines company Biological E Ltd for early-stage research and development of a six-in-one combination paediatric vaccine to help protect children in India and other developing markets, a move that will strengthen the multinational giant's position in the Rs 1,800-crore Indian vaccine market. 

Under the equal joint venture agreement, both companies will develop a six-in-one vaccine for polio and other infectious diseases, reinforcing their commitment to work with the World Health Organisation (WHO) to eradicate polio. 

"This agreement is fully aligned with GSK's vision of providing high-quality vaccines to those in need and by leveraging Biological E's strengths, this particular vaccine has the potential to play a significant role in the fight against polio," said Christophe Weber, president of GSK Vaccines.